Actively Recruiting
Study of Alpha-Lipoic Acid Added to Mesalamine to Treat Mild to Moderate Ulcerative Colitis
Led by Tanta University · Updated on 2025-02-06
60
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the efficacy and safety of alpha-lipoic acid combined with mesalamine in patients with mild to moderate ulcerative colitis. This study focuses on alpha-lipoic acids antioxidant and anti-inflammatory properties, which may help improve the condition. The trial is designed as a randomized, single-blind study led by Tanta University. Participants will be randomly assigned to one of two groups. One group receives mesalamine 1000 mg three times daily plus a placebo once daily, while the other group receives mesalamine 1000 mg three times daily plus alpha-lipoic acid 600 mg once daily. The treatment lasts for three months. During the study, participants will be monitored for changes in health-related quality of life and disease severity after three months of treatment. Biological markers such as fecal calprotectin, reduced glutathione, interleukin-6, and transforming growth factor-beta 1 will also be measured. The study includes regular assessments to track safety and effectiveness throughout the treatment period.
CONDITIONS
Brief Title
Alpha Lipoic Acid in Ulcerative Colitis
Research Team
A
Ahmed Farouk
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
